First Berlin puts Marinomed rating, price target under review

PUBT · 2d ago
First Berlin puts Marinomed rating, price target under review
  • First Berlin Equity Research cut Marinomed to Under Review from Buy on restructuring risk tied to failed Unither talks.
  • Report cited plans for court-supervised restructuring without self-administration as liquidity pressure raised insolvency risk.
  • Earn-out payments from the Carragelose sale have not been received; up to EUR 15 million had been expected to fund EIB repayments.
  • Outstanding debt totals EUR 3.8 million, with EUR 1.45 million due in November 2026 and EUR 2.37 million due in May 2027.
  • Analyst Alexander Rihane put the price target under review, citing legal and financial uncertainty around the process.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marinomed Biotech AG published the original content used to generate this news brief via EQS News (Ref. ID: rc_26214) on July 20, 2026, and is solely responsible for the information contained therein.